Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis

Journal of Drug Targeting

Volumn 15, Issue 6, 2007, Pages 437-444

  Gupta, Swati ^a,b   Dube, Anuradha ^b   Vyas, Suresh P ^a  

^a DR H S GOUR UNIVERSITY   (India)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Amphotericin B; Emulsomes; Macrophage targeting; O palmitoyl mannan; Visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; MANNAN; MYCOL; O PALMITOYL MANNAN; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; ENCAPSULATION; HAMSTER; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA DONOVANI; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VISCERAL LEISHMANIASIS;

AMPHOTERICIN B; ANIMALS; CRICETINAE; DEOXYCHOLIC ACID; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG COMBINATIONS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MACROPHAGES; MALE; MESOCRICETUS; MICE; NANOPARTICLES; TRYPANOCIDAL AGENTS;

EID: 34447504406     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860701453836     Document Type: Article

References (48)

1. Agrawal, AK, Agrawal, A., Pal, A., Guru, PY and Gupta, CM (2002) Superior chemotherapeutic efficacy of amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamsters. J Drug Target, 10, pp. 41-45.
2. Ahmad, I., Sarkar, AK and Bachhawat, BK (1989) Design of liposomes to improve delivery of amphotericin B in the treatment of aspergillosis. J Mol Cell Biochem, 91, pp. 85-90.
3. Alving, CR, Weldon, JS, Munnell, JF and Hanson, WL (1984) Liposomes in leishmaniasis: The lysosome connection. Receptor mediated targeting of drugs, 82, pp. 317-331. Plenum Press, New York and London
4. Amselem, S., Yogev, A., Zawoznik, E. and Friedman, D. (1994) Emulsomes, a novel drug delivery technology. Proc Int Symp Control Release Bioact Mater, 21, pp. 1368-1369.
5. Banerjee, G., Nandi, G., Mahato, SB, Pakrashi, A. and Basu, MK (1996) Drug delivery system: Targeting of pentamidines to specific sites using sugar-grafted liposomes. J Antimicrob Chemother, 38, pp. 145-150.
6. Banerjee, G., Medda, S. and Basu, MK (1998) A novel peptide-grafted liposomal delivery system targeted to macrophages. Antimicrob Agents Chemother, 42, pp. 348-351.
7. Berman, JD, Hanson, WL, Chapman, WL, Alving, CR and Lopez-Berestein, G. (1986) Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob Agents Chemother, 30, pp. 847-851.
8. Bora, D. (1999) Epidemiology of visceral leishmaniasis in India. Natl Med J India, 12, pp. 62-68.
9. Das, PK, Murray, GJ, Zairzow, GC, Brady, RO and Barranger, JA (1985) Lectin specific targeting of β-glucocerebrosidase to different liver cells via glycosylated liposomes. Biochem Med, 33, pp. 124-131.
10. Das, N., Mahato, SB, Naskar, K., Ghosh, DK and Basu, MK (1990) Targeting of urea stibamine encapsulated in liposomes to reticuloendothelial system for the treatment of experimental leishmaniasis. Biochem Med Metab Biol, 43, pp. 133-139.
11. Dea-Ayuela, MA, Rama-Iniguez, S., Sanchez-Brunete, JA, Torrado, JJ, Alunda, JM and Bolas-Fernandez, F. (2004) Anti-leishmanial activity of a new formulation of amphotericin B. Trop Med Int Health, 9, pp. 981-990.
12. Dube, A., Sharma, P., Srivastava, JK, Misra, A., Naik, S. and Katiyar, JC (1998) Vaccination of langur monkeys (Presbytis entellus) against Leishmania donovani with autoclaved L. major plus BCG. Parasitology, 116, pp. 219-221.
13. Dube, A., Srivastava, JK, Sharma, P., Chaturvedi, A., Katiyar, JC and Naik, S. (1999) Leishmania donovani: Cellular and humoral immune responses in Indian langur monkeys, Presbytis entellus. Acta Tropica, 73, pp. 37-48.
14. Dube, A., Singh, N., Sundar, S. and Singh, N. (2005) Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. Parasitol Res, 96, pp. 216-223.
15. Echevarria, I., Barturen, C., Renedo, MJ, Troconiz, IF and Dios-Vieitez, MC (2000) Comparative pharmacokinetics, tissue distributions, and effects on renal function of novel polymeric formulations of amphotericin B and amphotericin B-deoxycholate in rats. Antimicrob Agents Chemother, 44, pp. 898-904.
16. Espuelas, MS, Legrand, P., Loiseau, PM, Bories, C., Barratt, G. and Irache, JM (2002) In vitro antileishmanial activity of amphotericin B loaded in poly (epsilon-caprolactone) nanospheres. J Drug Target, 10, pp. 593-599.
17. Fry, DW, White, JC and Goldman, ID (1978) Rapid separation of low molecular weight solutes from liposomes without dilution. Anal Biochem, 90, pp. 809-815.
18. 125I labelled γ-globulin encapsulated in liposomes. Biochim Biophys Acta, 632, pp. 560-565.
19. Goldsmith, DR and Perry, CM (2004) Amphotericin B lipid complex: In visceral leishmaniasis. Drugs, 64, pp. 1905-1911.
20. Gupta, S. and Vyas, SP (2007) Development and characterization of amphotericin B bearing emulsomes for passive and active macrophage targeting. J Drug Target, 15, pp. 206-217.
21. Guru, PY, Agarwal, AK, Singha, UK, Singhal, A. and Gupta, CM (1989) Drug targeting in Leishmania donovani infections using tuftsin bearing liposomes as drug vehicles. FEBS Lett, 245, pp. 204-208.
22. Hartsel, S. and Boland, J. (1996) Amphotericin B: New life for an old drug. Trends Pharmacol Sci, 17, pp. 445-449.
23. Hiemenz, JW and Walsh, TJ (1996) Lipid formulations of amphotericin B: Recent progress and future directions. Clin Infect Dis, 22, pp. S133-S144.
24. Kafetzis, DA, Velissariou, IM, Stabouli, S., Mavrikou, M., Delis, D. and Liapi, G. (2005) Treatment of paediatric visceral leishmaniasis: Amphotericin B or pentavalent antimony compounds?. Int J Antimicrob Agents, 25, pp. 26-30.
25. Khan, MA, Nasti, TH and Owais, M. (2005) Incorporation of amphotericin B in tuftsin-bearing liposomes showed enhanced efficacy against systemic cryptococcosis in leucopenic mice. J Antimicrob Chemother, 56, pp. 726-731.
26. Kole, L., Sarkar, K., Mahato, SB and Das, PK (1994) Neoglycoprotein conjugated liposomes as macrophage specific drug carrier in the therapy of leishmaniasis. Biochem Biophy Res Commun, 200, pp. 351-358.
27. Kretschmar, M., Amselem, S., Zawoznik, E., Mosbach, K., Dietz, A., Hof, H. and Nichterlein, T. (2001) Efficient treatment of murine systemic infection with Candida albicans using amphotericin B incorporated in nanosize range particles (emulsomes). Mycoses, 44, pp. 281-286.
28. Lowell, GH, Kaminski, RW, VanCott, TC, Slike, B., Kersey, K., Zawoznik, E., Loomis-Price, L., Smith, G., Redfield, RR, Amselem, S. and Birx, DL (1997) Proteosomes, emulsomes, and cholera toxin B improve nasal immunogenicity of human immunodeficiency virus gp160 in mice: Induction of serum, intestinal, vaginal, and lung IgA and IgG. J Infect Dis, 175, pp. 292-301.
29. Melby, PC (2002) Recent developments in leishmaniasis. Curr Opin Infect Dis, 15, pp. 485-490.
30. Mitra, M., Mandal, AK, Chatterjee, TK and Das, N. (2005) Targeting of mannosylated liposome incorporated benzyl derivative of Penicillium nigricans derived compound MT81 to reticuloendothelial systems for the treatment of visceral leishmaniasis. J Drug Target, 13, pp. 285-293.
31. Mullen, AB, Baillie, AJ and Carter, KC (1998) Visceral leishmaniasis in the BALB/c mouse: A comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B. Antimicrob Agents Chemother, 42, pp. 2722-2725.
32. New, RRC (1990) Introduction and preparation of liposomes. Liposomes: A practical approach, pp. 1-104. IRL Press, Oxford
33. Pal, R., Dube, A., Rizvi, SY, Kundu, B., Mathur, KB and Katiyar, JC (1991) Leishmania donovani in hamsters: Stimulation of non-specific resistance by some novel glycopeptide and impact on therapeutic efficacy. Experientia, 47, pp. 486-490.
34. Rex, JH and Walsh, TJ (1999) Estimating the true cost of amphotericin B. Clin Infect Dis, 29, pp. 1408-1410.
35. Rocheleau, H., Saint-Germain, G., Barwicz, J., Gruda, I. and Therien, HM (1994) Modulation of amphotericin B activity by association with mannose ester. Immunopharmacol Immunotoxicol, 16, pp. 419-436.
36. Sanchez-Brunete, JA, Dea, MA, Rama, S., Bolas, F., Alunda, JM, Raposo, R., Mendez, MT, Torrado-Santiago, S. and Torrado, JJ (2004) Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres. Antimicrob Agents Chemother, 48, pp. 3246-3252.
37. Saxena, S. and Ghosh, PC (2000) Biodistribution of amphotericin B when delivered through cholesterol hemisuccinate vesicles in normal and A. fumigatus infected mice. Pharm Res, 17, pp. 1236-1242.
38. Sunamoto, J., Gato, M., Iida, T., Hara, K., Saito, A. and Tomonega, A. (1985) Polymer coated liposomes for drug delivery to target specific organs. Receptor mediated targeting of drugs, pp. 359-371. Plenum Press, New York
39. Sundar, S. and Rai, M. (2002) Advances in the treatment of leishmaniasis. Curr Opin Infect Dis, 15, pp. 593-598.
40. Szoka, FC and Mayhew Jr, E. (1983) Alteration of liposome disposition in vivo by bilayer situated carbohydrates. Biochim Biophys Res Commun, 110, pp. 140-147.
41. Townsed, RW, Zutshi, A. and Bekersky, I. (2001) Biodistribution of 4-[(14)C] cholesterol-AmBisome following a single intravenous administration to rats. Drug Metab Dispos, 29, pp. 681-685.
42. Venier-Julienne, MC, Vouldoukis, I., Monjour, L. and Benoit, JP (1995) In vitro study of the anti-leishmanial activity of biodegradable nanoparticles. J Drug Target, 3, pp. 23-29.
43. Venkatesan, N. and Vyas, SP (2000) Polysaccharide coated liposomes for oral immunization: Development and characterization. Int J Pharm, 203, pp. 169-177.
44. Vyas, SP, Katare, YK, Mishra, V. and Sihorkar, V. (2000) Ligand directed macrophage targeting of amphotericin B loaded liposomes. Int J Pharm, 210, pp. 1-14.
45. Vyas, SP, Quraishi, S., Gupta, S. and Jaganathan, KS (2005) Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages. Int J Pharm, 296, pp. 12-25.
46. Vyas, SP, Subhedar, R. and Jain, S. (2006) Development and characterization of emulsomes for sustained and targeted delivery of an antiviral agent to liver. J Pharm Pharmacol, 58, pp. 321-326.
47. Wong-Beringer, A., Jacobs, RA and Guglielmo, BJ (1998) Lipid formulations of amphotericin B: Clinical efficacy and toxicities. Clin Infect Dis, 27, pp. 603-618.
48. Yachi, K., Kikuchi, H., Yamauchi, H., Hirota, S. and Tomikawa, M. (1995) Distribution of liposomes containing mannobiose esters of fatty acid in rats. J Microencapsul, 12, pp. 377-388.